Hanh Thi My Pham

Hanh Thi My Pham


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
TTThuy T. Trinh
Thuy T. Trinh
KNKien D. Nguyen
Kien D. Nguyen
HPHuong V. Pham
Huong V. Pham
THThang V. Ho
Thang V. Ho
HNHuong T. Nguyen
Huong T. Nguyen
HPHanh Thi My Pham
Hanh Thi My Pham

23 December 2023 in Technology Analysis & Strategic Management
Verified
Journal Article
Closed access
NVNam Hoang Vu
Nam Hoang Vu
THTram Bao Hoang
Tram Bao Hoang
HPHanh Thi My Pham
Hanh Thi My Pham
Tuan-Anh BuiTuan-Anh Bui
Tuan-Anh Bui

26 November 2025 in Clinical and Experimental Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
HTHang Doan Thi
Hang Doan Thi
DNDang Kien Nguyen
Dang Kien Nguyen
TTTung Nguyen Thanh
Tung Nguyen Thanh
NNNhat Nguyen Ngoc
Nhat Nguyen Ngoc
HPHanh Thi My Pham
Hanh Thi My Pham
STSon Trinh The
Son Trinh The
Background: In assisted reproductive technology, particularly in vitro fertilization (IVF), optimizing ovarian stimulation protocols using individualized recombinant follicle-stimulating hormone (FSH) preparations, such as follitropin delta, has gained attention for its potential to improve treatment outcomes and reduce the risk of ovarian hyperstimulation syndrome (OHSS). This study aimed to evaluate the efficacy of combining follitropin delta and clomiphene citrate (CC) in women with a suboptimal response to ovarian stimulation using follitropin alpha during IVF. Methods: A retrospective study was conducted in women undergoing two consecutive IVF cycles at the Military Institute of Clinical Embryology and Histology, Vietnam. The first cycle utilized follitropin alpha, followed by a second cycle with follitropin delta plus CC. Embryological outcomes were assessed, including the number of stimulated follicles, the number of oocytes retrieved, and embryo quality at cleavage and blastocyst stages. A mixed-effects model with a negative binomial or Poisson distribution was applied to analyze repeated measurements within the same individual. Results: A total of 57 women were included in the final analysis. Following a suboptimal response to follitropin alpha, ovarian stimulation with follitropin delta plus CC resulted in a significant increase in the number of total day 3 embryos (p = 0.018), total day 5–6 embryos (p = 0.017), and good-quality blastocysts (p = 0.028). The number of stimulated follicles also showed a trend toward improvement (p = 0.043). No significant differences were observed in the number of oocytes retrieved or metaphase II (MII) oocytes. Conclusions: In women who previously demonstrated a suboptimal ovarian response, follitropin delta combined with CC was associated with improved embryological outcomes compared to conventional follitropins. These findings suggest that combining follitropin delta and CC may optimise ovarian response and embryo quality in this patient population. Further studies are warranted to confirm these results and assess the impact of this combination treatment on clinical pregnancy and live birth rates.